Research Reports

Prepared Highlights

Q3 2025 net sales $533M, +6% actual / +5% CER, exceeding 4% CER target (CEO). Core sales (excl. discontinued products) +6% CER (CEO).
Adjusted diluted EPS $0.61 (actual & CER), above outlook of ≥$0.58 (CEO).
QIAstat diagnostics +11% CER, driven by double-digit consumable growth and strong placements (CEO). QuantiFERON +11% CER, supported by latent TB conversion (CEO).
Sample technologies returned to growth: +3% CER, led by automated consumables (CEO). QIAcuity (digital PCR) double-digit CER growth, consumables offsetting slower instrument sales (CEO).
QIAGEN Digital Insights (bioinformatics) double-digit CER growth, including Genoox contribution (CEO).
Adjusted operating income margin 29.6% (Q3), 30% CER, absorbing >150 bps headwinds from currency and U.S. tariffs (CFO).
9M 2025 underlying operating cash flow $466M (incl. ~$45M restructuring payments); free cash flow $336M (CFO).
Capital allocation: announced $500M synthetic share repurchase (closing Jan 2026); total shareholder return since 2024 now above 2028 goal of ≥$1B (CEO). Also acquired Parse Biosciences for single-cell technology (CEO).
Balance sheet: net debt/adjusted EBITDA expected to move toward ~2x industry average during 2026 (CFO).
Official guidance: Full-year 2025 net sales growth ~4–5% CER (confirmed); core portfolio growth ~5–6% CER (confirmed); adjusted EPS raised to ~$2.38 CER (up $0.10 from initial guidance). Q4 2025: total net sales steady vs Q4 2024 CER, core sales ~2% CER, adjusted EPS ~$0.60 CER (CFO).
Mgmt quotes:
- "the 24th consecutive quarter in which we met or exceeded our targets." (CEO)
- "We continue to see the clear merits of our strategy to prioritize high-growth areas of molecular research and testing…" (CEO)
- "QIAGEN remains one of the fastest-growing companies in our industry as core sales rose 6% at constant exchange rates." (CFO)
- "We are also on track to move well above our 31% adjusted operating income target by the end of 2028 despite currency and integration headwinds." (CEO)
- "This performance in 2025 also enables us to advance key capital allocation initiatives that are strengthening our business and creating value." (CEO)

Prepared Metrics

Metric	Value	Speaker/Context
Q3 net sales	$533M	CEO
Q3 net sales growth (CER)	+5%	CEO, vs 4% target
Core sales growth (CER)	+6%	CEO, Q3 2025
Adjusted diluted EPS (Q3)	$0.61 (actual & CER)	CEO, above ≥$0.58 outlook
Adjusted operating income margin (Q3)	29.6% of sales (30% CER)	CFO
R&D spending (Q3)	9.2% of sales	CFO
SG&A (Q3)	21.2% of sales	CFO, down from 22.2% YoY
9M 2025 operating cash flow	$466M	CFO, incl. ~$45M restructuring
9M 2025 free cash flow	$336M	CFO
AR days (end Q3 2025)	~53 days	CFO, vs ~56 days at end 2024
Inventory days (end Q3 2025)	151 days	CFO, vs 193 days at end 2024
FY2025 adjusted EPS guidance (CER)	~$2.38	CFO, raised $0.10 from initial
Q4 2025 adjusted EPS guidance (CER)	~$0.60	CFO
Total shareholder return since 2024 (objective)	≥$1B by end 2028	CEO, already above with new $500M repurchase

Q&A Batch (1-5 of 8)

Q1 — Jack Meehan

Topic: Parse 收购的战略价值与技术差异化
Key points:
- Parse 是单细胞分析领域增长最快的公司，已进入超过 3,000 个实验室。
- 提供无仪器的试剂盒，可处理数百万至数十亿个细胞，远超竞争对手（如 10x Genomics）。
- 收购具有战略协同性，将结合 QDI 的 AI 驱动工具，预计在不到 3 年内实现财务增值（top-line 增长和 EPS 增厚）。
Mgmt stance: bullish，因强调自然延伸、执行记录和明确财务回报。

Q2 — Hugo Solvet

Topic: QIAstat 增长趋势与新面板推动
Key points:
- Q3 实现 11% 增长（呼吸道淡季），新增 150 台系统装机。
- GI 和脑膜炎面板在美国及北欧/中东地区增长超过两位数，美国是主要市场。
- 2026 年计划推出血培养面板，2026–2027 年推出复杂 UTI 面板，将丰富菜单。
- 预计将超越 2028 年 2 亿美元的中期收入目标，巩固市场第二位置。
Mgmt stance: bullish，因已实现双位数增长且未来产品管线清晰。

Q3 — Douglas Schenkel

Topic: QIAstat 美国布局与 QuantiFERON 竞争力
Key points:
- 2025 年上半年美国装机量已超过 2024 年全年；每个区域配备专属销售代表。
- QuantiFERON 第四代已与 DiaSorin、Tecan、Hamilton 建立自动化合作。
- 全球仍有超过 5,000 万皮肤测试待转化（美国约 1,500 万），皮肤测试仍是主要竞争对手。
- 即将公告 workflow 改进和测试增强，无自满情绪。
Mgmt stance: bullish，因市场份额领先且持续投资防御竞争。

Q4 — Casey Woodring

Topic: 美国政府关门对学术和政府市场的影响
Key points:
- 保守假设关门持续至年底，影响每日消耗品和仪器销售。
- 公司产品价值高、单价低，可部分缓解；影响已纳入 2025 年指引。
- 维持全年收入指引并提高盈利指引（ adjusted EBIT margin）。
Mgmt stance: neutral/cautious，承认冲击但认为可控，且通过保持指引展示韧性。

Q5 — Aisyah Noor

Topic: 关税影响与定价转嫁能力
Key points:
- 2025 年关税净影响为 90 个基点（利润率），缓解措施将于明年初生效，不预期扩大。
- 附加费为谈判过程，客户理解价值，未观察到需求延迟。
- 2023–2025 年 adjusted EBIT 利润率从 26.9% 提升至 30%（+310bps），体现管理能力。
Mgmt stance: bullish，因能成功转嫁并持续扩大利润率。

Q&A Batch (6-8 of 8)

Q6 — Patrick Donnelly

Topic: 2026年营收与利润率展望
Key points:
- 2025年Q4预计恒定汇率EBIT利润率约30%，实际受汇率负面影响后约29.5%。
- 2026年预计潜在利润率改善，但关税和Argos收购带来一定逆风。
- 若市场环境不改善，2026年营收增长约5%（含Parse收购），若改善可至5-7%；非正式指引。
- 管理层重申7% CAGR和31% EBIT margin的长期承诺，并计划通过收购（Genoox、Parse）和成本行动支撑EPS。
Mgmt stance: 中性偏积极 – 虽下调短期增长预期，但强调通过资本配置和运营优化仍能达成市场EPS预期。

Q7 — Luke Sergott

Topic: Parse收购的协同效应及QIAcuity表现
Key points:
- Parse已有3,000+客户，无仪器依赖，具备giga lab产能；预计通过QIAGEN全球网络扩大地理覆盖。
- QIAcuity消耗品双位数增长，其中biopharma QC增长超双位数，CDx（数字PCR伴随诊断）增速更快。
- 每季度仍安装超100台QIAcuity系统，但低资本支出环境抑制新